Biomarker Discovery for Cancer Vaccine

The low success rate of immunotherapy for cancer requires us to understand the immune mechanism in depth, and the determination of biomarkers that can predict the therapeutic effect may be a means to enhance the success of cancer vaccines. Besides that, it is exciting that progress in sequencing technology and omics has also brought bright hopes to this strategy. Creative Biolabs has an advanced sequencing platform and a wealth of research strategies and technologies to discover and identify multiple types of biomarkers while meeting your requirements for precision, breadth and high throughput for your cancer vaccine development as well as saving your time and effort in developing cancer vaccine.

Background

In recent years of cancer research, advances in immuno-oncology are noteworthy. The goal of Immuno-oncology is to uncover new biomarkers and identify new therapeutic targets to provide new ideas for the treatment of cancer. However, the complexity of the relationship between tumor biology, the tumor microenvironment, and the immune system has made past methods unable to provide sufficient data on the discovery and identification of biomarkers. More and more new technologies are showing potential in studying the relationship between tumors and the immune system. The cancer biomarker can be a molecule released by a tumor or a reaction of the immune system to a tumor, which can characterize the occurrence and development of cancer in the body. Various biomarkers, including genetic, proteomic, epigenetic, and imaging biomarkers play important roles in the diagnosis and prognosis of cancer, and these biomarkers can be detected in serum or blood samples. Tumor-associated biomarkers can provide guidance for the clinical treatment of tumors, and are more and more related to molecular pathway regulation and the pathogenesis of tumors.

The patient's immune status is the key to determining the disease’s progression, but there is currently no single measure for assessing immunity. Therefore, it is particularly important to be able to identify the markers capable of predicting the possible response after vaccination.

Discovery of Biomarkers for Cancer Vaccine

Scientists have identified a number of potential biomarkers that can predict vaccine immunogenicity, and the emergence of multiple detection and analysis tools has made biomarker discovery and validation possible. There are three issues to consider when identifying biomarkers. First, whether the immune response stimulated by immunotherapy can predict the therapeutic effect. Second, whether it is possible to determine the pre-treatment factors that can predict the therapeutic immune response. Third, whether the pre-treatment factors that predict the therapeutic effect can be determined.

Schematic of a pathway to identify relevant biomarkers capable of predicting immunological and clinical efficacy - Creative Biolabs

Fig.1 Schematic of a pathway to identify relevant biomarkers capable of predicting immunological and clinical efficacy.

Strategies for Cancer Biomarker Discovery

Genetic sequencing: exome, whole genome, transcriptome sequencing, chip expression analysis
Protein biomarkers: mass spectrometry, peptidomics, immunohistochemistry, secreted proteins, biomarker families, protein arrays, tumor-associated antigens
Metabolic biomarkers: NMR, HPLC, radioimmunoassay, LCMS, GCMC, enzyme-linked immunosorbent assay
microRNA biomarker: chip analysis, qRT-PCR

Highly Accurate and Rich Content Sequencing (HARCS) Platform

The HARCS platform provides you with improved, more comprehensive, high-throughput sequencing and analysis services that dramatically increase your efficiency and success in cancer biomarker discovery.

Typical Features of HARCS Platform

Accuracy	Highly enhanced resolution, capable of detecting large numbers of subtle DNA changes Enabling the optimization of different conditions for sequencing high GC content regions, structural variant regions, repeat sequences, compressions, etc., and merging data with scientific algorithms to ensure sequencing accuracy
Multiple testing items	Exome sequencing Including single nucleotide polymorphisms (SNPs) Whole genome sequencing including Structural variants (SVs) and copy number variation (CNV) detection
Broad coverage	Covering outside the exome Focusing on biomedically important part of the genome

Creative Biolabs has a passion for human health and has been focusing on vaccine research for decades. We have advanced technology platforms and strategies for the discovery and identification of cancer biomarkers with high accuracy and our unique patented technology for deep sequencing of the complex structure of the genome will be the powerful support for your cancer vaccine.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.